This study will look at how an investigational drug called GZR18 works in your body by:
Atherosclerotic Cardiovascular Disease (ASCVD) is a type of heart disease that happens when plaque builds up in the arteries, resulting in risk for a heart attack or stroke. ASCVD is the most common type of cardiovascular disease in the United States, and ASCVD is also the leading cause of death for people of most racial/ethnic groups in the United States. In some cases, learning more about a person’s eye health can help us learn more about a person’s risk for developing ASCVD, including risk for future heart attacks or strokes. This research is being done to investigate artificial intelligence (AI) software called CLAiR, which is used to analyze a type of eye photograph called a retina image. Retinal images are photos that are taken of your retinas. Your retina is the light sensitive part of the back of your eye that is responsible for vision. In this study, CLAiR will be used to look at retinal images from each of your eyes and help to determine if a person between the ages of 40-75 is at higher risk for developing ASCVD.
The primary purpose of this study is to utilize the FSL3 to help prolong the length of time people with diabetes maintain adherence to GLP-1 and GIP/GLP-1 antagonists. Subjects with type 2 diabetes who are newly beginning glucagon-like peptide 1 (GLP-1) and dual gastric inhibitory polypeptide/glucagon-like peptide 1 (GIP/GLP-1) agonist therapy will be assigned to use either the FSL3 or their existing Standard of Care (SOC) device to manage their type 2 diabetes. Effectiveness will be characterized by assessing the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drug.
The purpose of this study is to find out about the safety and effectiveness of monthly study treatment with abelacimab (hereafter referred to as the study drug) in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners.
We are doing this study to learn more about how safe the study drug AZD6234 is and how it affects your medical condition of overweight or obesity with type 2 diabetes when you are given the study drug AZD6234 along with a specific therapy called glucagon like peptide-1 receptor agonist (GLP-1 RA). Additional aims of the study are to better understand overweight or obesity with type 2 diabetes.
Amylin is a hormone that plays an important role in body weight management. The study drug AZD6234 can mimic amylin’s effects in the body and may aid in weight management, potentially helping with weight management and type 2 diabetes.
We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems. Combining balcinrenone with Dapagliflozin is experimental, which means it is not approved by any health authority such as the United States Food and Drug Administration (FDA). Dapagliflozin is an approved drug to treat patients with heart failure, chronic kidney disease and type 2 diabetes mellitus.
The purpose of this clinical research study is to look at how safe and effective ARO-APOC3 is at lowering triglycerides in people with hypertriglyceridemia.
Hypertriglyceridemia is a condition where there is a high level of a certain kind of fat (called triglycerides) in the blood. The human body needs some triglycerides for good health. If the level of triglycerides in the blood becomes too high, it can lead to heart disease (such as blood vessel disease, stroke, or heart attack) or pancreatitis.
This study is comparing how well BGF (brand name BREZTRI) or GFF (brand name BEVESPI) may help prevent COPD flare-ups and serious heart events in people with COPD. People with COPD have a higher risk of heart problems and serious heart events than people without COPD.
Inhaled corticosteroids (ICS) are known to help prevent COPD flare-ups. It is thought that combination treatments with inhaled corticosteroids (ICS) may help reduce serious heart events. For this reason, we will compare a treatment with an ICS (BGF) against one without an ICS (GFF).
The purpose of this research is to find out how well using Continuous Glucose Monitoring (CGM) works to improve glucose control compared to routine care (RC) in people with type 2 diabetes not taking insulin. Routine care for a person with type 2 diabetes is typically to check blood glucose by fingerstick at certain times rather than using a CGM. Comparing CGM and routine care is experimental.
The purpose of this clinical research trial is to look at the effectiveness, safety, and tolerance of combining the investigational trial drug called BI 690517 with empagliflozin (empa) in participants diagnosed with heart failure (HF). Empagliflozin is approved by the FDA for the treatment of heart failure.
In this trial, the investigational new treatment option BI 690517 is compared with a treatment with empa and placebo. You have a 50% chance (much like flipping a coin) of getting BI 690517 with empa, or empa and placebo. Please be aware that you may receive placebo that looks like the trial drug (BI 690517) but does not contain any medicine.
The recently completed dal-GenE study, a clinical trial of over 6,000 patients, evaluated the effects of dalcetrapib in patients with recent ACS and the AA genetic variant. The results of this large study demonstrated that treatment with dalcetrapib did not change the risk of having another cardiovascular event in the majority of patients with recent ACS. However, an analysis was performed which indicated that the COVID-19 pandemic may have impacted the accuracy of this data. When the results collected before the start of the COVID-19 pandemic were evaluated, certain analyses showed that taking dalcetrapib corresponded to a reduction in chance of experiencing a myocardial infarction (heart attack) when compared to those taking placebo (dummy drug). The goal of the present study is to evaluate the effect of dalcetrapib only in patients with the AA genetic variant to confirm these findings of cardiovascular benefit.
The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism. This study will compare the effect of Armour Thyroid on hypothyroidism and its safety with synthetic drug T4 (Levothyroxine).
The number of FDA-approved and commercially available options for the treatment of hypothyroidism are limited. Currently, synthetic T4 is the common thyroid replacement therapy. Prior to the mid-1970s, desiccated thyroid, such as Armour Thyroid, was the most commonly prescribed form of thyroid hormone replacement. Some of the patients treated with synthetic T4 continue to have persistent symptoms of hypothyroidism or inadequate improvement of their hypothyroid symptoms. The use of desiccated thyroid (Armour Thyroid) may be beneficial to patients with hypothyroidism.
This study is being done to see how safe an investigational drug is and how well it will work to help people with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 and heart related and/or kidney related disease. “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this study drug for research.
The main purpose of this study is to learn more about retatrutide (LY3437943), which is an investigational treatment for participants with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 (kilogram per square meter) and heart related and/or kidney related disease.
The study drug ZT-01 is designed to inhibit somatostatin, a hormone that inhibits the glucagon response to hypoglycemia. Thus, ZT-01 may be able to restore glucagon production to prevent hypoglycemia, which could improve both health and quality of life in people with T1DM.
The purpose of this study is:
This trial is testing an experimental drug called MK-0616 in people with high cardiovascular risk.
The purpose of this trial is to:
A placebo looks like the trial drug, but it has no active ingredients.
We understand that enrolling in a clinical trial can raise many questions. How long will the trial last? Are there costs involved? What happens if the treatment doesn’t work for me? Our comprehensive FAQ section is here to address these concerns and more, empowering you with the knowledge you need to make an informed decision. Our goal is to provide answers with empathy and honesty, ensuring you feel supported at every stage of your trial participation. For further details or specific concerns, Read More FAQs to explore all the insights available.
Headquarters
3550 University Blvd South, Suite #101
Jacksonville, FL 32216
Tel: (904) 854-1354
Fax: (904) 854-1355
